Atorvastatin Induced Erythrocytes Membrane Blebbing.
calcium
cell size
eryptosis
oxidative stress
Journal
Dose-response : a publication of International Hormesis Society
ISSN: 1559-3258
Titre abrégé: Dose Response
Pays: United States
ID NLM: 101308899
Informations de publication
Date de publication:
Historique:
received:
15
05
2019
revised:
02
07
2019
accepted:
18
07
2019
entrez:
27
8
2019
pubmed:
27
8
2019
medline:
27
8
2019
Statut:
epublish
Résumé
Atorvastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzymeA reductase, is usually used for the treatment of hypercholesterolemia. Besides its pharmacological and side actions, its toxic effects on human nucleus devoid of erythrocytes are still unknown. Eryptosis is an alternative term used for suicidal erythrocyte death. Membrane blebbing is among the common markers of eryptosis. In this study, eryptotic effect of atorvastatin was investigated by exposing the erythrocytes for 48 hours to different concentrations (1-10 µM) of atorvastatin. The experimental work related to investigation of eryptosis was done by cell size measurement and calcium channel inhibition. As a possible mechanism of eryptosis, atorvastatin-induced oxidative stress was evaluated by determining catalase, glutathione peroxidase, and superoxide dismutase activities. Similarly, necrotic effect of atorvastatin was also determined by hemolytic assay. Results of our study illustrated that the tested doses of atorvastatin may induce oxidative stress as observed by significant reduction in superoxide dismutase, glutathione peroxidase, and catalase activities as well as induce eryptosis, featured by erythrocytes membrane blebbing. The study concluded that induction of oxidative stress by atorvastatin may lead to eryptosis.
Identifiants
pubmed: 31447619
doi: 10.1177/1559325819869076
pii: 10.1177_1559325819869076
pmc: PMC6691667
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1559325819869076Déclaration de conflit d'intérêts
Declaration of Conflicting Interests: The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
Teratology. 2000 Oct;62(4):234
pubmed: 10992266
J Appl Toxicol. 2001 Jan-Feb;21(1):69-73
pubmed: 11180282
Cell Death Differ. 2001 Dec;8(12):1197-206
pubmed: 11753567
J Physiol. 2002 Mar 15;539(Pt 3):847-55
pubmed: 11897854
Cell Death Differ. 2003 Feb;10(2):249-56
pubmed: 12700653
Nature. 1992 Jan 23;355(6358):353-6
pubmed: 1309940
Methods Biochem Anal. 1954;1:357-424
pubmed: 13193536
Am J Physiol Cell Physiol. 2003 Dec;285(6):C1553-60
pubmed: 14600080
Indian J Med Res. 2005 Feb;121(2):111-5
pubmed: 15756044
Plant Physiol. 1977 Feb;59(2):315-8
pubmed: 16659840
Antioxid Redox Signal. 2006 Jul-Aug;8(7-8):1183-92
pubmed: 16910766
Biophys J. 2008 Mar 1;94(5):1836-53
pubmed: 17921219
Cell Physiol Biochem. 2008;22(5-6):373-80
pubmed: 19088418
J Exp Med. 1947 Sep 30;86(4):339-56
pubmed: 19871682
Dent Mater J. 2010 Jan;29(1):75-83
pubmed: 20379016
Pharmacogn Rev. 2010 Jan;4(7):69-76
pubmed: 22228944
Int J Biochem Cell Biol. 2012 Aug;44(8):1236-43
pubmed: 22561748
Cell Physiol Biochem. 2012;30(3):512-22
pubmed: 22814298
Toxins (Basel). 2013 Apr 19;5(4):703-16
pubmed: 23604064
Biogerontology. 2013 Oct;14(5):461-82
pubmed: 24057278
Basic Clin Pharmacol Toxicol. 2014 Nov;115(5):396-402
pubmed: 24717091
Toxins (Basel). 2014 May 13;6(5):1559-74
pubmed: 24828755
Physiol Res. 2015;64(6):891-6
pubmed: 26047376
Food Chem Toxicol. 2015 Sep;83:36-47
pubmed: 26051349
Int J Clin Exp Med. 2015 Mar 15;8(3):3371-80
pubmed: 26064227
Antioxid Redox Signal. 2016 Jan 10;24(2):84-98
pubmed: 26414931
Eur J Clin Invest. 2015 Dec;45(12):1316-24
pubmed: 26479159
Blood. 1995 Feb 1;85(3):818-23
pubmed: 7833482
J Clin Invest. 1993 Jul;92(1):520-6
pubmed: 8326017
Clin Chem. 1998 May;44(5):924-9
pubmed: 9590363